Shows / BiotechTV - News
BiotechTV - News
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
BiotechTV - NewsBenchtalk 2025: Dyne Therapeutics' CSO Ron Batra describes the company's FORCE platform, and previews big trial scheduled in DMD and DM1 over the next year
He describes the science behind FORCE, which combines an antigen-binding fragment, a linker and, a payload. The company's DMD program will have a key trial…
BiotechTV - NewsSunrise Group, which has designed a mandibular sensor for at-home diagnosis of sleep apnea, recently raised $29M to expand its digital sleep clinic that patients can access remotely
Co-Founder & CEO Laurent Martinot discusses the raise, and the need for more accessible sleep health care. Plus, previewing a clinical trial of its device that…
BiotechTV - NewsOxford's OrganOx became one of the UK's biggest news stories when it was announced it would be acquired by Japan's Terumo for approximately $1.5 billion - here's the revolutionary technology behind it
CEO Craig Marshall describes how the company's "metra" device pumps blood through donor organs (currently livers) in order to extend the amount of time they…
BiotechTV - NewsOxford, UK based OMass Therapeutics, experts in the use of mass spectrometry in drug development, recently landed a $20M up front licensing deal with Roche on one of its preclinical candidates for IBF
CEO Ros Deegan discusses the deal and the path to getting there, and she highlights some of OMass' other programs the company is driving forward alone…
BiotechTV - NewsNYSE Market Strategist Eric Criscuolo discusses biotech's newfound momentum and whether it might attract generalists to take a look at the sector
He discusses the rally biotech has had of late, and that was boosted by Pfizer's deal with the White House. Plus, how interest rates, employment, and other…
BiotechTV - NewsImmuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'
Ben Zeskind describes the company's 9 month follow-up for atebimetinib + mGnP, which showed 86% overall survival and 53% progression free survival.
BiotechTV - NewsR.W. Baird Managing Director & Senior Biotech Analyst Brian Skorney discusses numerous battleground companies in biotech
He shares his thoughts on Soleno, Sarepta, Lexeo, Enanta, Crinetics, Vertex, Xenon, and more.
BiotechTV - NewsBiotech veteran David Hung talks about the launch of IBTROZI in ROS1 positive non-small cell lung cancer, and what's next for Nuvation Bio
He discusses the clinical profile of IBTROZI, how the launch is going, and describes other work the company is doing in precision medicine. Plus, his take on…
BiotechTV - NewsComplement Therapeutics received IND clearance from U.S. FDA today to start a trial of its AAV gene therapy for geographic atrophy that delivers a truncated version of Complement Receptor 1 to the eye
CEO Rafiq Hasan describes to BiotechTV's Amy Brown during an interivew in London how this program works, and he compares and contrasts it to more traditional…
BiotechTV - NewsAlign Summit: Cambridge based Quiver Bioscience is developing ASOs for CNS conditions, including having programs in the red hot Nav1.7/1.8 pain space
Co-Founder & CEO Graham Dempsey describes the different between Nav1.7 and 1.8, and why he thinks having an ASO approach will succeed in 1.7 where small…
BiotechTV - NewsAlign Summit: Toronto based HDAX Therapeutics believes there are many indications to tackle with its dual binding approach to HDAC6
Co-Founder & CEO Nabanita Nawar describes the need for tackle HDAC6 with better chemistry. Plus, what it is like being a biotech startup in Canada today.
BiotechTV - NewsAlign Summit: Allston based KiraGen Bio is aiming to program CAR-T cells to tune out the suppressive nature of the tumor micro environment. The first program will be for GBM.
Co-Founder and CEO Aaron Edwards describes the rational behind this approach, as opposed charging the cells with cytokines or removing their brakes. He also…
BiotechTV - NewsSoufflé Therapeutics exited stealth today with the goal of developing nucleic acid therapies, like siRNAs and ASOs, delivered to any cell in the body by targeting internalizing receptors
CEO Amir Nashat, who has decades of experience in biotech at Polaris Partners, describes the work Soufflé has been doing to catalogue often rare targets and…
BiotechTV - NewsBrian Alexander, former CEO of Foundation Medicine, describes how Valo Health is using its AI expertise to partner with companies and foundations on discovery and development projects
The company recently received a grant from the Michael J. Fox Foundation to work on Parkinson's, and has existing partnerships with companies such as Novo and…
BiotechTV - NewsAerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies across the BBB
Chief Executive Officer Jack O'Meara, who previously founded Ochre Bio in the RNA space, describes the potential benefits of using brain shuttles and why the…
BiotechTV - NewsEnanta Pharmaceuticals' CEO and CMO discuss data announced today on the company's RSV treatment, Zelicapavir, and describe the road ahead for this program and the company
CEO Jay Luly and CMO Scott Rottinghaus describe today's data, which was focused on high risk adults. They explain how safety and efficacy were measured, and…
BiotechTV - NewsSunny Kumar, a partner at Informed Ventures, and an active investor in the AI space, talks about current and future implications of AI's impact on healthcare
He discussed how current technologies are making healthcare more effecient today, how new technologies are opening new markets, and how the practice of…
BiotechTV - NewsEko Health's Co-Founder & CEO shows BiotechTV the company's digital stethoscope and explains how having both an electric and sound component can help physicians catch heart disease (and more) earlier
Connor Landgraf shows us the product and describes recent data the company compiled in the UK showing the benefits of using this digital and AI enhanced device…
BiotechTV - NewsSweden's Annoca announced a $46M raise last month to help move its first TCR-T program into the clinic for KRAS-driven pancreatic cancer. CEO Reagan Jarvis tells us about that work and more.
He describes the raise and the trial, which is an umbrella study that will test products against three different mutations. Plus, work on vaccines and a…
BiotechTV - NewsXspray Pharma makes protein kinase inhibitors that are amorphous, and therefore more soluble than current products. Dasynoc, its version of dasatinib (Sprycel), is in front of FDA with an Oct 7 PDUFA
CEO Per Andersson walks us through the benefits of designing kinase inhibitors this way, which should not be affected by the pH of the stomach. He shows us the…
BiotechTV - NewsPareto Securities Healthcare Conference: Egetis Therapeutics has a therapy for a rare disease called MCT8 deficiency that is approved by the EMA and has breakthrough therapy designation in the U.S.
CEO Nicklas Westerholm walks us through the condition, which is an X-chromosome linked rare disease that affects men, and he describes how the launch is going…
BiotechTV - NewsPareto Securities' Healthcare Conference: Cinclus Pharma is trying to user in the next generation of acid reflux medicines with, linaprazan glurate, a potassium-competitive acid blocker (P-CAB)
CEO Christer Ahlberg describes the shortcomings of today's medicines, and why he believes a P-CAB is the answer. This therapy originated at AstraZeneca, though…
BiotechTV - NewsPareto Securities' Healthcare Conference: Biotech Analyst Dan Akschuti shares his take on the the conference and the state of biotech, and highlights key companies to watch in the region
He sees an optimistic turn after a challenging couple of years. Plus, highlighting Vicor, Camurus, Oculis, and BioArctic.
BiotechTV - NewsPareto Securities' Healthcare Conference: Saniona has built expertise in the ion channel space, in addition to its own work, it has partnerships with Jazz, Acadia, and others
CEO Thomas Feldthus describes the challenge of making ion channel medicines selective enough to avoid unwanted side effects. He walks us through the Jazz and…
BiotechTV - NewsPareto Securities' Healthcare Conference: BioArctic's CEO Gunilla Osswald highlights the company's brain transporter technology, the latest on Leqembi, and a Parkinson's program
She describes the transferrin receptor based brain transporter technology, which the company recently signed another new partner (Novartis) on for $30M up…
BiotechTV - NewsPareto Securities' Healthcare Conference: Guard Therapeutics will have a key P2b trial read for its kidney protecting therapy RCM-035 in the 4th quarter - CEO Tobias Agervald walks us through it
He describes the science behind the A1M protein that this is based on, and how Guard has chosen kidney protection for patients who are undergoing heart surgery…
BiotechTV - NewsPareto Securities' Healthcare Conference: BioInvent has recently optimized its pipeline to focus on two key programs - BI-1808, the anti-TNFR2 antibody, and BI-1206, an FcγRIIB inhibitor
CEO Martin Welschof walks us through these two programs, which both target liquid and solid tumors. BI-1808 recently had data at EHA and will have solid tumor…
BiotechTV - NewsPareto Securities Healthcare Conference: Basilea is using its financial strength from two marketed products to develop its pipeline and acquire new products - it just received more BARDA funding today
CEO David Veitch walks us through the U.S. launch of Zevtera, and discusses where Cresemba is in its global commercial lifecycle. Plus, pipeline progress, and…
BiotechTV - NewsTakeda's CEO Christophe Weber describes the company's landmark phase 3 data that was presented at World Sleep Congress this week for its first-in-class orexin agonist for treating narcolepsy type 1
Christophe Weber discusses the 25 year journey from the discovery that orexin deficiency is the cause of narcolepsy to announcing two positive phase three…
BiotechTV - NewsLeaders of Brandon Capital, a seed and VC firm formed in Australia and with an office in the UK as well, discuss their $290 million sixth fund
Founding Partner Stephen Thompson and Partner Jonathan Tobin list some of their recent investments, highlight the advantage of running speedy clinical trials…
BiotechTV - NewsBiotech veteran Harvey Berger was named Chairman & CEO of Arena BioWorks today - he describes how 'foraging to focusing' will be the name of the game
Dr. Berger, whose experience in biotech goes back decades, including founding and running ARIAD for 25 years, is taking over this company that was publicly…
BiotechTV - NewsStevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS
CEO Neil Miller walks us through the hypothesis of how toxic proteins created by neurodegenerative diseases enter and damage the mitochondria, and how the…
BiotechTV - NewsFairtility has received FDA clearance on its AI-based embryo assessment tool for IVF, CHLOE Blast, that helps embryologists with embryo and oocyte assessments
Co-Founder and CEO Eran Eshed describes the unmet need and how CHLOE Blast analyzes images from a time-laps incubator.
BiotechTV - NewsN-Power Medicine launched what it is calling the 'Industry’s First Prospective External Control Arm Platform' for cancer trials - Mark Lee, CEO and a medical oncologist, explains why and how it works
He describes how the idea is to cut down on control arm overlap used in numerous trials. If successful, it might free up space and resources to run faster and…
BiotechTV - NewsCytokinetics' CEO Robert Blum discusses the result of the MAPLE-HCM study of aficamten, and other learnings from the European Society of Cardiology Congress 2025
He shares what he believes the takeaways are from MAPLE-HCM, which studied aficamten vs a beta blocker in symptomatic obstructive hypertrophic cardiomyopathy…
BiotechTV - NewsJohn Maraganore and Clive Meanwell are launching Corsera Health out of stealth - which, through a combo of predictive diagnostics and an RNAi targeting PCSK9 and angiotensinogen, aims extend lifespans
Launched publicly today, and funded with $50M at this point, Corsera Health hopes to target those who are most at risk for atherosclerotic cardiovascular…
BiotechTV - NewsThe CEO of Tennr, which raised a $101M series C earlier this summer, explains how the company's platform uses large language models to make the patient referral process to specialists more efficient
Trey Holterman describes how Tennr is trying to fix this process which relies on significant unstructured data and has traditional leads to onerous delays and…
BiotechTV - NewsStanford professor James Zou and his team created a virtual lab with AI scientists - they designed nanobodies for a COVID variant
Dr. Zou describes this work, which was published recently in Nature, and how the the AI scientists were able to do everything from debate internally to narrow…
BiotechTV - NewsWilliam Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron
He shares his take on today's data, which saw Viking's stock decline by over 40%, and Lilly's earlier data which also sparked a Wall Street disappointment. He…
BiotechTV - NewsCelebrating the 2025 Nucleate Alumni Summit
Nucleate leaders describe what Nucleate has done for their education and career, and what they are looking forward to at this year's global summit in Boston.
BiotechTV - NewsAfter exiting stealth with $20 million two weeks ago, Orchestra Bio is out to help science entrepreneurs handle the dollars and cents management and long term planning that business requires
Founder & CEO Ashoka Rejendra describes what the company offers, which is a not only a software package, but guidance on how to build and plan for the future…
BiotechTV - NewsBiotech Direct: MassBio CEO Kendalle Burlin O'Connell and Seaport Therapeutics Founder & CEO Daphne Zohar discuss NIH funding, recent developments at FDA, and improving the public's view of science
In this inaugural episode of Biotech Direct, BiotechTV's new show that will share the biotech industry's perspective on policy and regulatory news, Kendalle…
BiotechTV - NewsIO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead
Dr. Zocca describes the results of the trial, which showed a 19.4 months vs. 11.0 months mPFS benefit versus pembro alone, but narrowly missed statistical…
BiotechTV - NewsChecking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna - the company's first (and first for the field) registration intended trial will read in the first half of 2026
Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna's most advanced programs. We discuss Stiff…
BiotechTV - NewsBay Area based Nosis Bio is leveraging AI to get its gene silencers specifically to precise cell types - it recently announced a development candidate to tackle fibrosis
Co-Founder & CEO Jim Martineau walks us through the platform and describes the importance of being cell type specific. The company utilized a combination of AI…
BiotechTV - NewsChecking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter
Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and explains why a new…
BiotechTV - NewsIDEAYA Biosciences is at the forefront of precision oncology - we discuss the pipeline, including a key pivotal trial that will read out for Darovasertib by the end of the year
Founder & CEO Yujiro Hata describes the idea behind precision medicine and synthetic lethality. We discuss the company's pipeline assets Darovasertib, a DLL3…
BiotechTV - NewsCytomX Therapeutics' years of work on its 'Probody' masking technology may be paying off at a time when there is growing focus on this approach - it presented key initial data on its EpCAM ADC in May
Chairman & CEO Sean McCarthy walks us through the science and describes what CytomX has learned about it over many years of working on masking. He discusses…
BiotechTV - NewsMaze Therapeutics, which had its IPO earlier this year, is using insights from genetics to develop small molecules - its most advanced program is for a genetic kidney disease
CEO Jason Coloma walks us through the science that is taking place at the company's South San Francisco headquarters, and descrbies the development programs…
BiotechTV - NewsAstria Therapeutics licensed its HAE treatment, Navenibart, to Kaken Pharmaceutical for the Japanese market. It is a kallikrein inhibitor that is in phase 3, and is dosed up to every six months
President and CEO Jill Milne describes what she believes is the unmet need and profile of Navenibart, and walks us through future anticipated developments…
BiotechTV - NewsAI News: While most AI in healthcare is aimed at helping physicians better diagnose and treat disease, CureWise is built for patients to help understand their conditions and ask the right questions
Founder & CEO Steve Brown, who created CureWise after receiving his own diagnosis of a rare blood cancer, describes his journey and how CureWise is meant to…
BiotechTV - NewsFrom Indianapolis: Serial entrepreneur Derek Small publicly launched a new neuroscience company with $90M earlier this summer, Syndeio Biosciences. He tells us about it and talks Indiana biotech.
He discusses the idea behind Syndeio, which focuses on synaptic function and has a lead program in major depressive disorder. Plus, other work he is doing, and…
BiotechTV - NewsFrom Indianapolis: Adipo Therapeutics is approaching the obesity space by trying to turn energy storing 'white' fat into energy burning 'brown' fat
CEO Karen Wurster describes the science behind the company, which recently presented proof-of-concept data from human cells at the ADA meeting. Plus, what it…
BiotechTV - NewsThe Indiana Biosciences Research Institute is a central hub for the biotech scene in Indiana - its CEO describes what it is all about, and the status of biotech here today
IBRI CEO Alan Palkowitz descrbies the work that takes place at the IBRI, which includes both the institute's own research and how it acts as an incubator to…
BiotechTV - NewsBiotechTV visits Indiana University School of Medicine's Stark Neurosciences Research Institute and discusses the latest in Alzheimer's research with its executive director, Bruce Lamb
Dr. Lamb, a noted expert in neuroscience and Alzheimer's research, introduces us to Stark and describes the investment in people and equipment that has been…
BiotechTV - NewsFormer NIH Director and Co-Founder of ModeX Therapeutics Elias Zerhouni shares his take on possible NIH cuts and the state of science in the United States, and working on multispecifics at his company
He highlights his new memoir, Disease Knows No Politics, and gives his opinion on what is at stake in preserving NIH and other scientific funding. Plus, how…
BiotechTV - NewsAI x Bio Summit: Proscia CEO David West describes how AI in pathology is not just helping pathologists find disease, but can also help get the right drug to the right patient
He describes how computing power in pathology is augmenting the work that pathologists traditionally do, but also is becoming an increasing important tool in…
BiotechTV - NewsMonte Rosa Therapeutics' CEO Markus Warmuth updates us on the company's progress in developing molecular glue degraders
The company, which recently had a paper earn a spot on the cover of Science, is progressing ahead with both I&I and oncology indications. Dr. Warmuth walks us…
BiotechTV - NewsAbivax CEO Marc de Garidel discusses Obefazimod's phase 3 trial result in ulcerative colitis, and what is next for the company
He covers the mechanism of action, this week's efficacy and safety data, what it might mean for the maintenance trial that will read out in 2Q26, additional…
BiotechTV - NewsAI x Bio Summit: Recursion's Chief R&D Officer & CCO Najat Khan describes how the company leverages AI - including in both the dry lab and the wet lab, and all through clinical trials
She describes Recursion's work, and what the acquisition of Exscientia has brought to the company. Plus, how AI can not only help with drug design, but also…